Abstract Details

Title Improvement of Troublesome Dyskinesia in People with Parkinson’s Disease Treated with Foslevodopa/Foscarbidopa

Topic Movement Disorders

Presentation(s) P7 - Poster Session 7 (5:00 PM-6:00 PM)

Poster/Presentation
Number 5-032

Objective This post hoc analysis evaluated LDp/CDp efficacy by baseline duration of troublesome dyskinesia.

Background Troublesome dyskinesia, a complication from Parkinson’s disease (PD) progression and pulsatile dopaminergic stimulation, impairs daily living. Foslevodopa/foscarbidopa (LDp/CDp), a formulation of levodopa/carbidopa prodrugs delivered as a continuous (24-hour/day) subcutaneous infusion, increased “On” time without troublesome dyskinesia in 2 phase 3 clinical trials.

Design/Methods Patients with levodopa-responsive idiopathic PD aged >=30 years who were inadequately controlled by current therapy and had >=2.5 “Off” hours/day received LDp/CDp in a 52-week, phase 3, open-label trial (NCT03781167). The change from baseline (CFB) to final visit was assessed for “On” time with troublesome dyskinesia (PD diary; normalized to 16-hour waking day), time spent with dyskinesias (Movement Disorder Society-Unified PD Rating Scale [MDS-UPDRS] Part 4.1), functional impact of dyskinesias (MDS-UPDRS Part 4.2), and 39-item PD Questionnaire (PDQ-39) in patient subgroups with >0.5 and >1.0 hours of troublesome dyskinesia at baseline.

Results Baseline characteristics were similar across subgroups with >0.5 (n=83) and >1.0 hours (n=66) of troublesome dyskinesia at baseline; mean (SD) duration of troublesome dyskinesia was 2.7 (2.0) and 3.1 (2.0) hours, respectively. In both subgroups, LDp/CDp led to numerical or significant improvements from baseline in troublesome dyskinesia (mean [SD] CFB −1.4 [3.4] and −2.5 [2.2] hours, respectively; P<.05), time spent with dyskinesias (P<=.001), functional impact of dyskinesias (P<=.001), and PDQ-39 (P<.05 for >0.5 hour subgroup).

Conclusions Continuous delivery of LDp/CDp was associated with significant improvements in dyskinesia and quality of life in patients with relevant/significant troublesome dyskinesia at baseline.

Authors/Disclosures
Linda Harmer, Other (AbbVie) PRESENTER	Ms. Harmer has received personal compensation for serving as an employee of AbbVie. Ms. Harmer has stock in AbbVie.
Morten Blaabjerg, MD (Odense Universitetshospital)	Dr. Blaabjerg has nothing to disclose.
Tsao-Wei Liang, MD (Thomas Jefferson University)	The institution of Dr. Liang has received research support from Bial R&D Investments S.A.. The institution of Dr. Liang has received research support from Parkinson's Foundation. The institution of Dr. Liang has received research support from AbbVie. The institution of Dr. Liang has received research support from Neuroderm. Dr. Liang has received publishing royalties from a publication relating to health care.
Elizabeth L. Peckham, DO	The institution of Dr. Peckham has received research support from abbvie. The institution of Dr. Peckham has received research support from lilly. The institution of Dr. Peckham has received research support from Amlyx. The institution of Dr. Peckham has received research support from Cerevel. The institution of Dr. Peckham has received research support from Sage. The institution of Dr. Peckham has received research support from Annovis. The institution of Dr. Peckham has received research support from AriBio. The institution of Dr. Peckham has received research support from Ferrer. The institution of Dr. Peckham has received research support from Biogen. The institution of Dr. Peckham has received research support from UCB. The institution of Dr. Peckham has received research support from Roche. The institution of Dr. Peckham has received research support from Cerevance. The institution of Dr. Peckham has received research support from Aptinyx.
Sarah E. Zauber, MD, FAAN (Indiana University School of Medicine)	Dr. Zauber has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ascel Health. The institution of Dr. Zauber has received research support from Abbive. The institution of Dr. Zauber has received research support from Abbott. Dr. Zauber has received personal compensation in the range of $500-$4,999 for serving as a Site Visitor with Parkinson Foundation.
Lars Bergmann, MD (Abbvie GmbH & Co)	Lars Bergmann has received personal compensation for serving as an employee of Abbvie. Lars Bergmann has stock in Abbvie.
Resmi Gupta (Abbvie Inc)	Resmi Gupta has nothing to disclose.
Megha Shah	Megha Shah has received personal compensation for serving as an employee of AbbVie. Megha Shah has stock in AbbVIe .
Filip Bergquist	The institution of Filip Bergquist has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Filip Bergquist has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Arvid Carlsson Research AB. The institution of Filip Bergquist has received research support from Swedish Government. The institution of Filip Bergquist has received research support from Parkinsonfonden. The institution of Filip Bergquist has received research support from Neuro Sweden. The institution of Filip Bergquist has received research support from Swedish Research Council. Filip Bergquist has received publishing royalties from a publication relating to health care. Filip Bergquist has received publishing royalties from a publication relating to health care. Filip Bergquist has a non-compensated relationship as a Advisor with Sense4Care that is relevant to AAN interests or activities.

��ɫ��

��ɫ��